431 related articles for article (PubMed ID: 21243454)
21. [Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine].
Pfaar O; Klimek L
HNO; 2007 Dec; 55(12):981-90; quiz 991-2. PubMed ID: 17992493
[TBL] [Abstract][Full Text] [Related]
22. Effects of omalizumab in patients with food allergy.
Rafi A; Do LT; Katz R; Sheinkopf LE; Simons CW; Klaustermeyer W
Allergy Asthma Proc; 2010; 31(1):76-83. PubMed ID: 20167148
[TBL] [Abstract][Full Text] [Related]
23. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
24. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
Kupryś-Lipińska I; Kuna P
Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
[TBL] [Abstract][Full Text] [Related]
25. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
26. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases.
Sarinho E; Cruz AA
J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S127-32. PubMed ID: 17136288
[TBL] [Abstract][Full Text] [Related]
27. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.
Iyengar SR; Hoyte EG; Loza A; Bonaccorso S; Chiang D; Umetsu DT; Nadeau KC
Int Arch Allergy Immunol; 2013; 162(1):89-93. PubMed ID: 23816920
[TBL] [Abstract][Full Text] [Related]
28. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
30. Omalizumab: a future innovation for treatment of severe ocular allergy?
Williams PB; Sheppard JD
Expert Opin Biol Ther; 2005 Dec; 5(12):1603-9. PubMed ID: 16318424
[TBL] [Abstract][Full Text] [Related]
31. Omalizumab.
Easthope S; Jarvis B
Drugs; 2001; 61(2):253-60; discussion 261. PubMed ID: 11270941
[TBL] [Abstract][Full Text] [Related]
32. Anti-IgE treatment: an update.
Babu KS; Arshad SH; Holgate ST
Allergy; 2001 Dec; 56(12):1121-8. PubMed ID: 11736740
[No Abstract] [Full Text] [Related]
33. Anti-IgE antibodies for the treatment of asthma.
Buhl R
Curr Opin Pulm Med; 2005 Jan; 11(1):27-34. PubMed ID: 15591885
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.
Sheinkopf LE; Rafi AW; Do LT; Katz RM; Klaustermeyer WB
Allergy Asthma Proc; 2008; 29(5):530-7. PubMed ID: 18926061
[TBL] [Abstract][Full Text] [Related]
37. Role of immunmodulators in allergen-specific immunotherapy.
Kopp MV
Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
[TBL] [Abstract][Full Text] [Related]
38. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
Lowe PJ; Renard D
Br J Clin Pharmacol; 2011 Aug; 72(2):306-20. PubMed ID: 21392073
[TBL] [Abstract][Full Text] [Related]
39. Omalizumab, an anti-immunoglobulin E antibody: state of the art.
Incorvaia C; Mauro M; Russello M; Formigoni C; Riario-Sforza GG; Ridolo E
Drug Des Devel Ther; 2014; 8():197-207. PubMed ID: 24532966
[TBL] [Abstract][Full Text] [Related]
40. Omalizumab: a monoclonal anti-IgE antibody.
Belliveau PP
MedGenMed; 2005 Jan; 7(1):27. PubMed ID: 16369332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
